Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more
Bluebird bio Inc (BLUE) - Net Assets
Latest net assets as of March 2025: $-57.87 Million USD
Based on the latest financial reports, Bluebird bio Inc (BLUE) has net assets worth $-57.87 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($295.96 Million) and total liabilities ($353.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-57.87 Million |
| % of Total Assets | -19.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.33% |
| 10-Year Change | -103.71% |
| Growth Volatility | 87.16 |
Bluebird bio Inc - Net Assets Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bluebird bio Inc (2011–2024)
The table below shows the annual net assets of Bluebird bio Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-31.53 Million | -116.21% |
| 2023-12-31 | $194.54 Million | -0.92% |
| 2022-12-31 | $196.34 Million | -47.54% |
| 2021-12-31 | $374.28 Million | -72.38% |
| 2020-12-31 | $1.36 Billion | +5.45% |
| 2019-12-31 | $1.28 Billion | -31.83% |
| 2018-12-31 | $1.89 Billion | +16.12% |
| 2017-12-31 | $1.62 Billion | +86.72% |
| 2016-12-31 | $869.44 Million | +2.23% |
| 2015-12-31 | $850.50 Million | +73.13% |
| 2014-12-31 | $491.26 Million | +223.91% |
| 2013-12-31 | $151.67 Million | +372.06% |
| 2012-12-31 | $-55.75 Million | -0.07% |
| 2011-12-31 | $-55.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bluebird bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 443760100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.92 Million | % |
| Other Comprehensive Income | $-2.13 Million | % |
| Other Components | $4.47 Billion | % |
| Total Equity | $-31.53 Million | 100.00% |
Bluebird bio Inc Competitors by Market Cap
The table below lists competitors of Bluebird bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
$48.34 Million |
|
Thai Nguyen International Hospital JSC
VN:TNH
|
$48.35 Million |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
$48.37 Million |
|
IZEA Inc
NASDAQ:IZEA
|
$48.38 Million |
|
Indian Hume Pipe Company Limited
NSE:INDIANHUME
|
$48.33 Million |
|
Wallbridge Mining Company Limited
OTCQB:WLBMF
|
$48.32 Million |
|
Prevas AB
ST:PREV-B
|
$48.32 Million |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
$48.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bluebird bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 194,537,000 to -31,534,000, a change of -226,071,000 (-116.2%).
- Net loss of 240,715,000 reduced equity.
- Other comprehensive income decreased equity by 2,133,000.
- Other factors increased equity by 16,777,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-240.72 Million | -763.35% |
| Other Comprehensive Income | $-2.13 Million | -6.76% |
| Other Changes | $16.78 Million | +53.2% |
| Total Change | $- | -116.21% |
Book Value vs Market Value Analysis
This analysis compares Bluebird bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-2.44 | $4.97 | x |
| 2012-12-31 | $-2.44 | $4.97 | x |
| 2013-12-31 | $6.35 | $4.97 | x |
| 2014-12-31 | $18.51 | $4.97 | x |
| 2015-12-31 | $24.53 | $4.97 | x |
| 2016-12-31 | $23.32 | $4.97 | x |
| 2017-12-31 | $37.29 | $4.97 | x |
| 2018-12-31 | $36.23 | $4.97 | x |
| 2019-12-31 | $23.28 | $4.97 | x |
| 2020-12-31 | $21.79 | $4.97 | x |
| 2021-12-31 | $5.43 | $4.97 | x |
| 2022-12-31 | $2.50 | $4.97 | x |
| 2023-12-31 | $1.01 | $4.97 | x |
| 2024-12-31 | $-3.25 | $4.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bluebird bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -287.23%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-44.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -1768.48% | 0.03x | 0.00x | $-10.03 Million |
| 2012 | 0.00% | -6961.76% | 0.00x | 0.00x | $-18.10 Million |
| 2013 | -16.70% | -125.47% | 0.09x | 1.48x | $-40.49 Million |
| 2014 | -9.92% | -191.61% | 0.05x | 1.13x | $-97.83 Million |
| 2015 | -19.61% | -1184.62% | 0.01x | 1.18x | $-251.83 Million |
| 2016 | -30.31% | -4281.19% | 0.01x | 1.29x | $-350.45 Million |
| 2017 | -20.67% | -947.42% | 0.02x | 1.17x | $-497.99 Million |
| 2018 | -29.48% | -1018.02% | 0.02x | 1.19x | $-744.13 Million |
| 2019 | -61.45% | -1767.49% | 0.03x | 1.34x | $-918.11 Million |
| 2020 | -45.66% | -246.75% | 0.14x | 1.31x | $-754.20 Million |
| 2021 | -150.33% | -15364.23% | 0.01x | 1.59x | $-600.07 Million |
| 2022 | -135.77% | -7411.12% | 0.01x | 2.83x | $-286.21 Million |
| 2023 | -108.93% | -718.42% | 0.05x | 3.18x | $-231.37 Million |
| 2024 | 0.00% | -287.23% | 0.18x | 0.00x | $-237.56 Million |
Industry Comparison
This section compares Bluebird bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bluebird bio Inc (BLUE) | $-57.87 Million | 0.00% | N/A | $48.34 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |